Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 11/20 | 0.45 |
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
| ▸ | CCR7 | P32248 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | CCR4 | P51679 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | MPL | P40238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459334 | 0.95 | RARB (0.51) | RARBRARACCR5CCR2CCR7 | |
| SCHEMBL3459331 | 0.95 | RARB (0.51) | RARBRARACCR5CCR2CCR7 | |
| SCHEMBL6341107 | 0.93 | RARB (0.40) | RARBRARACCR5CCR2CCR7 | |
| SCHEMBL6343536 | 0.92 | RARB (0.39) | RARBRARACCR5CCR2CCR7 | |
| SCHEMBL6349978 | 0.91 | MPL (0.39) | RARBRARACCR5MPL | |
| SCHEMBL6350067 | 0.91 | CCR5 (0.45) | RARBRARACCR5CCR2CCR7 | |
| SCHEMBL6342363 | 0.87 | RXRA (0.39) | CCR5 | |
| SCHEMBL6342375 | 0.86 | CCR5 (0.38) | RARBRARACCR5CCR2CCR7 | |
| SCHEMBL5654599 | 0.86 | CCR5 (0.55) | RARBRARACCR5CCR2CCR7 | |
| SCHEMBL3458669 | 0.86 | CCR5 (0.49) | RARBRARACCR5CCR2CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-6936602-B1 | Benzazepine derivatives, process for the preparation of the same and uses thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-1186604-A1 | BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | RARB 2991/4885RARA 3618/4885CCR5 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.